Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
NAD+ Precursors (NMN & NR): Evidence Summary
Evidence summary for NAD+ Precursors (NMN & NR) across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to NAD+ Precursors (NMN & NR) overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| NAD+ blood level elevation | Tier A | 20 | Consistent 40-100% NAD+ increase across multiple RCTs for both NMN and NR |
| Muscle function improvement | Tier C | 2 | Small Phase 1 trials show improved strength and walking speed in elderly |
| Metabolic health | Tier C | 5 | Improved insulin sensitivity in overweight subjects; larger trials needed |
| Anti-aging / lifespan extension | Tier D | 0 | Strong preclinical data but no human lifespan or disease modification evidence |
References (3)
- NMN dose-ranging study in healthy middle-aged adults — Yi L, Maier AB, et al. . GeroScience (2022) PMID: 36482258
- NMN supplementation and muscle function in older men — Igarashi M, Nakagawa-Nagahama Y, et al. . NPJ Aging (2022) DOI: PMC9158788
- Nicotinamide riboside is safely tolerated and elevates NAD+ in healthy volunteers — Airhart SE, Shireman LM, et al. . PLoS ONE (2017) PMID: 29184669